Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Cureskin aims to disrupt the large and growing skin and hair care industry in India
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The company has received five final approvals
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Subscribe To Our Newsletter & Stay Updated